Drugs / TP03HN106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06482892 | Jul 2024 → Sep 2025 overdue | limb ischemia | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP03HN106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06482892 ↗ |
| Route | Intravenous | “intravenous injection of TP03HN106” NCT06482892 ↗ |